Lycia Therapeutics Launches U.S. IPO For Food Allergy, Graves' Disease Pipeline (LYCA)
· seekingalpha.com
Lycia Therapeutics' IPO, if fairly priced, is likely to attract strong interest, given early positive data and solid biopharma performance. Read more on LYCA.
Donovan Jones is an IPO research specialist with 15 years of experience analyzing investment opportunities for U.S. IPOs.He also leads the investing group IPO E...